This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Abnova
product type :
antibody
product name :
KRT6 monoclonal antibody, clone Ks6.KA12
catalog :
MAB5176
quantity :
1 mL
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
reactivity :
human, mouse
application :
western blot, immunohistochemistry - paraffin section, immunohistochemistry - frozen section
product information
catalog id :
MAB5176
product name :
KRT6 monoclonal antibody, clone Ks6.KA12
product description :
Mouse monoclonal antibody raised against native KRT6.
clone name :
Ks6.KA12
isotype :
IgG1
gene name :
KRT6A
gene alias :
CK6A CK6C CK6D K6A K6C K6D KRT6C KRT6D
gene description :
keratin 6A
immunogen :
Native purified human KRT6.
form :
Liquid
recommend dilutions :
Immunohistochemistry (1:10). The optimal working dilution should be determined by the end user.
storage buffer :
In Tris, pH7.4 (0.5% BSA, 0.09% sodium azide)
storage instruction :
Store at 4 C.
note :
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
type clonality :
Antibody
raised in host species :
Mouse
antigen species target species :
Human
specificity :
This antibody represents an excellent marker for non-keratinized squamous epithelia and proliferating cells of epidermis (e.g. within psoriatic lesions). It is suitable for discrimination of keratinizing and non-keratinizing squamous cell carcinoma versus e.g. poorly differentiated adenocarcinoma. Polypeptide reacting: Mr 56000 polypeptide (cytokeratin 6) of human squamous epithelia.
species reactivity cross reactivity :
Human,Mouse
application key :
WB,IHC-Fr,IHC-P
size :
1 mL
autodate :
2010-01-04
updatetime :
2011-10-19 17:24:28
company information
Abnova
9th Fl., No.108, Jhouzih St.
Neihu District. Taipei City
114 Taiwan
Neihu District. Taipei City
114 Taiwan
sales@abnova.com
https://www.abnova.com877-853-6098
questions and comments